

## Anti-Mouse CD18 SAFIRE Purified

Catalogue Number : 10212-25

RUO: For Research Use Only. Not for use in diagnostic procedures.

### Product Information

**Clone:** M18/2

**Format/Conjugate:** SAFIRE Purified

**Concentration:** 1 mg/mL

**Reactivity:** Mouse

**Laser:** Not Applicable

**Peak Emission:** Not Applicable

**Peak Excitation:** Not Applicable

**Filter:** Not Applicable

**Brightness (1=dim,5=brightest):** Not Applicable

**Isotype:** Rat IgG2a, kappa

**Formulation:** Phosphate-buffered aqueous solution, pH7.2.

**Storage:** Product should be kept at 2-8°C.

**Applications:** FC, FA

### Description

The M18/2 monoclonal antibody specifically binds to mouse CD18, a 95kDA integrin beta 2 glycoprotein. CD18 is expressed on all leukocytes with the highest density by NK and T cells. CD18 forms LFA-1 with CD11a, Mac-1 with CD11b and gp150/95 with CD11c. Through these interactions, CD18 has an important role in cellular adhesion. The M18/2 antibody is reported to stimulate Mac-1 and LFA-1 adhesion to their ligands and block tumor cell metastasis.

### Preparation & Storage

The product should be stored undiluted at 4°C. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography. The endotoxin level is determined by LAL test to be less than 0.01 EU/μg of the protein.

### Application Notes

The antibody has been analyzed for quality through the flow cytometric analysis of the relevant cell type. It is recommended that the reagent be titrated for optimal performance for each application.

### References

1. Driessens, M. H., Van Hulten, P., Zuurbier, A., La Riviere, G., Roos, E. (1996). Inhibition and stimulation of LFA-1 and Mac-1 functions by antibodies against murine CD18. Evidence that the LFA-1 binding sites for ICAM-1,-2, and-3 are distinct.; *Journal of leukocyte biology*.;60(6), 758-765.
2. Zahalka, M. A., Naor, D. (1994). &beta;2-Integrin dependent aggregate formation between LB T cell lymphoma and spleen cells: assessment of correlation with spleen invasiveness.; *International immunology*.;6(6), 917-924.
3. Isobe, M., Yagita, H., Okumura, K., Ihara, A. (1992). Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1.; *Science*,255(5048), 1125-1127.